Brought to you by 
Escalier Biosciences brings in $19mm through Series B round
19 Mar 2018
Executive Summary
Escalier Biosciences BV (RORyt (retinoic acid receptor-related orphan receptor gamma) compounds for dermatology and auto-immune conditions) closed a $19mm Series B round led by new backer Forbion (adds one of its partners to Escalier's board), which was joined by returning investors New Science Ventures and BioGeneration Ventures (BGV).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Escalier Biosciences brings in $19mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice